| Primary |
| Prostate Cancer |
63.6% |
| Product Used For Unknown Indication |
25.2% |
| Prostate Cancer Metastatic |
3.5% |
| Pain |
2.1% |
| Cellulitis |
1.4% |
| Cardiac Disorder |
0.7% |
| Drug Use For Unknown Indication |
0.7% |
| Metastases To Bone |
0.7% |
| Nasopharyngitis |
0.7% |
| Prophylaxis |
0.7% |
| Sleep Disorder |
0.7% |
|
| Injection Site Reaction |
19.7% |
| Injection Site Cellulitis |
10.6% |
| Pyrexia |
9.1% |
| Convulsion |
4.5% |
| Injection Site Pain |
4.5% |
| Intentional Drug Misuse |
4.5% |
| Interstitial Lung Disease |
4.5% |
| Pain |
4.5% |
| Vomiting |
4.5% |
| Cellulitis |
3.0% |
| Drug Ineffective |
3.0% |
| Incorrect Dose Administered |
3.0% |
| Injection Site Mass |
3.0% |
| Nausea |
3.0% |
| Pancytopenia |
3.0% |
| Peripheral Embolism |
3.0% |
| Pneumonia |
3.0% |
| Prostate Cancer |
3.0% |
| Prostatic Specific Antigen Increased |
3.0% |
| Shock |
3.0% |
|
| Secondary |
| Product Used For Unknown Indication |
24.2% |
| Prostate Cancer |
17.0% |
| Crohn's Disease |
9.1% |
| Chronic Obstructive Pulmonary Disease |
7.3% |
| Hypertension |
5.5% |
| Pain |
4.8% |
| Insomnia |
4.2% |
| Benign Prostatic Hyperplasia |
3.6% |
| Cardiovascular Event Prophylaxis |
3.6% |
| Diabetes Mellitus |
3.6% |
| Drug Use For Unknown Indication |
3.6% |
| Prostate Cancer Metastatic |
3.0% |
| Blood Cholesterol Increased |
1.8% |
| Hypothyroidism |
1.8% |
| Micturition Urgency |
1.8% |
| Blood Pressure |
1.2% |
| Chemotherapy |
1.2% |
| Hypocalcaemia |
1.2% |
| Back Pain |
0.6% |
| Blood Pressure Abnormal |
0.6% |
|
| Syncope |
24.0% |
| Syncope Vasovagal |
12.0% |
| Blood Testosterone Decreased |
8.0% |
| Deafness |
8.0% |
| Prostate Cancer |
8.0% |
| Prostatic Specific Antigen Increased |
8.0% |
| Renal Failure Acute |
8.0% |
| Erectile Dysfunction |
4.0% |
| Hot Flush |
4.0% |
| Interstitial Lung Disease |
4.0% |
| Osteoarthritis |
4.0% |
| Rhabdomyolysis |
4.0% |
| Urinary Tract Infection |
4.0% |
|
| Concomitant |
| Prostate Cancer |
19.0% |
| Prostate Cancer Metastatic |
16.5% |
| Constipation |
9.1% |
| Product Used For Unknown Indication |
9.1% |
| Metastases To Bone |
6.6% |
| Osteopenia |
5.0% |
| Prophylaxis |
4.1% |
| Gastrooesophageal Reflux Disease |
3.3% |
| Oedema |
3.3% |
| Osteoarthritis |
3.3% |
| Arthralgia |
2.5% |
| Atrial Fibrillation |
2.5% |
| Back Pain |
2.5% |
| Bone Disorder |
2.5% |
| Hypertension |
2.5% |
| Dyspepsia |
1.7% |
| Hormone-refractory Prostate Cancer |
1.7% |
| Hypokalaemia |
1.7% |
| Metastatic Pain |
1.7% |
| Peripheral Vascular Disorder |
1.7% |
|
| Anaemia |
7.4% |
| Fatigue |
7.4% |
| Myocardial Ischaemia |
7.4% |
| Rash |
7.4% |
| Renal Failure |
7.4% |
| Sepsis |
7.4% |
| Thrombocytopenia |
7.4% |
| Bacterial Infection |
3.7% |
| Death |
3.7% |
| Dizziness |
3.7% |
| Dry Skin |
3.7% |
| General Physical Condition Abnormal |
3.7% |
| Headache |
3.7% |
| Hepatic Failure |
3.7% |
| Hypocalcaemia |
3.7% |
| Incorrect Route Of Drug Administration |
3.7% |
| Lethargy |
3.7% |
| Low Density Lipoprotein Increased |
3.7% |
| Malaise |
3.7% |
| Metastases To Large Intestine |
3.7% |
|
